{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupDescription":"The relationship between the peak serum isotretinoin concentration level with event-free survival was explored with a Cox proportional hazards model. Eligible patients treated with isotretinoin on A3973, ANBL0032, ANBL0532, or ANBL0931 with peak serum concentration level data were included in the analysis.","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.6853","paramType":"Hazard Ratio (HR)","paramValue":"1.015","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"9.22","value":"1.00"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"12.93","value":"1.36"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"11.78","value":"1.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"Median peak serum concentration level of isotretinoin for patients enrolled on ANBL0532","dispersionType":"Full Range","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"},{"description":"Patients that either failed during Induction therapy or refused randomization","id":"OG002","title":"Not Assigned"}],"paramType":"MEDIAN","populationDescription":"Eligible patients evaluated for peak serum concentration level of isotretinoin.","reportingStatus":"POSTED","timeFrame":"Day 1 of each course","title":"Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies","type":"SECONDARY","unitOfMeasure":"Micromolar"}